Researchers have successfully used CRISPR-armed bacteriophages to treat a severe infection caused by antibiotic-resistant E. coli in a human patient, according to work highlighted in New Scientist. The approach combines two powerful biological tools: phages, viruses that naturally kill bacteria, and CRISPR gene-editing technology that targets and destroys bacterial DNA.
The patient suffered from a chronic wound infection resistant to standard antibiotics, leaving few treatment options. The therapeutic phages were engineered to carry CRISPR components that could identify and dismantle the genetic material of the resistant E. coli strain. This dual mechanism allows the phages to kill bacteria both through their natural predatory behavior and by rendering the pathogen's DNA nonfunctional.
Antibiotic resistance represents a growing public health threat. The World Health Organization estimates that drug-resistant infections kill at least 700,000 people annually, with projections suggesting 10 million deaths per year by 2050 if left unaddressed. Current antibiotics lose effectiveness as bacteria evolve resistance mechanisms. Phage therapy offers an alternative strategy that bacteria find harder to counter.
The engineered phages demonstrated ability to eliminate the problematic bacterial strain in the patient's infection. The CRISPR components improved the phages' effectiveness by targeting specific genetic sequences unique to the resistant strain, potentially reducing off-target effects on beneficial bacteria that typically colonize human tissues.
This case represents an important proof-of-concept for phage-CRISPR combinations against multidrug-resistant pathogens. However, significant limitations remain. Individual case reports cannot establish broad clinical efficacy or safety profiles. Larger clinical trials would be necessary to determine whether this approach works consistently across different patients and bacterial strains. Regulatory pathways for phage-based therapeutics remain underdeveloped compared to traditional pharmaceuticals.